Holen Sie sich die Stockscreener-App
9.67
6.93%
-0.72
Schlusskurs vom Vortag:
$10.39
Offen:
$10.32
24-Stunden-Volumen:
741.55K
Relative Volume:
1.91
Marktkapitalisierung:
$488.60M
Einnahmen:
$82.71M
Nettoeinkommen (Verlust:
$-102.24M
KGV:
-2.6349
EPS:
-3.67
Netto-Cashflow:
$-76.57M
1W Leistung:
+2.98%
1M Leistung:
-15.55%
6M Leistung:
-24.69%
1J Leistung:
-32.09%
1-Tages-Spanne:
$9.61
$10.60
1-Wochen-Bereich:
$9.21
$10.83
52-Wochen-Spanne:
$8.94
$20.70
Urogen Pharma Ltd Stock (URGN) Company Profile
Firmenname
Urogen Pharma Ltd
Sektor
Branche
Telefon
972 9 770 7601
Adresse
9 HA'TA'ASIYA ST, RA'ANANA
Vergleichen Sie URGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
9.67 | 488.60M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-19 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2024-08-22 | Eingeleitet | Guggenheim | Buy |
| 2023-02-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-27 | Eingeleitet | Berenberg | Buy |
| 2020-04-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-13 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-09 | Eingeleitet | National Securities | Neutral |
| 2019-05-30 | Eingeleitet | JP Morgan | Neutral |
| 2019-05-29 | Eingeleitet | Goldman | Neutral |
| 2019-01-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-04-04 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-11-15 | Bestätigt | Oppenheimer | Outperform |
| 2017-11-15 | Herabstufung | Raymond James | Outperform → Mkt Perform |
Alle ansehen
Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten
Alliancebernstein L.P. Buys 175,859 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Scotiabank Initiates UroGen Pharma at Sector Outperform With $23 Price Target - MarketScreener
UroGen Announces Data Presentations at the American Urological A - GuruFocus
UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers - The Joplin Globe
Wellington Management Group LLP Boosts Stake in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy - Seeking Alpha
KLP Kapitalforvaltning AS Acquires Shares of 5,500 UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma stock hits 52-week low at $9.02 - Investing.com Australia
UroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
UroGen Pharma stock hits 52-week low at $9.02 By Investing.com - Investing.com Canada
Long Term Trading Analysis for (URGN) - news.stocktradersdaily.com
UroGen Pharma Ltd (URGN) gets rating Resumed from Ladenburg Thalmann - knoxdaily.com
Charles Schwab Investment Management Inc. Boosts Position in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Earnings call transcript: UroGen Pharma Q4 2024 reports mixed results - Investing.com India
Bank of New York Mellon Corp Increases Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Transitional Cell Carcinoma Treatment Market Size in 7MM - openPR
UroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Recommendation of “Buy” from Analysts - Defense World
HC Wainwright Expects Reduced Earnings for UroGen Pharma - Defense World
(URGN) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Urogen pharma outlines $1B revenue potential for UGN-102 with June 2025 launch target - MSN
UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strat - GuruFocus.com
UroGen Pharma (NASDAQ:URGN) Price Target Cut to $55.00 by Analysts at HC Wainwright - Defense World
UroGen Pharma stock target cut to $55 at H.C. Wainwright By Investing.com - Investing.com Australia
UroGen Pharma stock target cut to $36 at Raymond James By Investing.com - Investing.com Australia
UroGen Pharma stock target cut to $36 at Raymond James - Investing.com India
UroGen Pharma stock target cut to $55 at H.C. Wainwright - Investing.com India
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2024 Earnings Call Transcript - Insider Monkey
UroGen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital - Defense World
UroGen Pharma Reports Strong Pipeline Progress and Revenue Growth - TipRanks
UroGen Pharma Ltd. SEC 10-K Report - TradingView
Earnings call transcript: UroGen Pharma Q4 2024 reports mixed results By Investing.com - Investing.com South Africa
UroGen Pharma shares fall as Q4 results miss estimates By Investing.com - Investing.com South Africa
UroGen Pharma shares fall as Q4 results miss estimates - Investing.com India
Urogen Pharma Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Urogen Pharma reports wider-than-expected fourth-quarter loss -March 10, 2025 at 10:56 am EDT - Marketscreener.com
Oppenheimer & Co. Inc. Acquires Shares of 11,875 UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma earnings missed by $0.03, revenue fell short of estimates - Investing.com Australia
UroGen Pharma Posts Wider Loss In Q4Quick Facts - Nasdaq
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102 - Joplin Globe
Rhumbline Advisers Has $546,000 Position in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph
UroGen Pharma Ltd. to Host Earnings Call - ACCESS Newswire
UroGen Pharma (URGN) to Release Earnings on Thursday - Defense World
BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight - GlobeNewswire Inc.
How to Take Advantage of moves in (URGN) - Stock Traders Daily
UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025 - StockTitan
Finanzdaten der Urogen Pharma Ltd-Aktie (URGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):